David joined the Sharpe Lab in January 2018 while a medical student in the Harvard/MIT Health Science and Technology (HST) program. In the Sharpe Lab, he studied the immune infiltrate of various tumor types and how these infiltrates change in response to checkpoint blockade therapy. Prior to coming to Harvard, David studied the common biochemical signals underlying oncogenesis in T cells.